Nuevas herramientas para el diagnóstico y el tratamiento de la enfermedad de hígado graso no alcohólico y la resistencia a insulina asociada a obesidad
- RAPOSO LOPEZ PASTOR, ANDREA
- Almudena Gómez Hernández Directrice
- Oscar Escribano Directeur
Université de défendre: Universidad Complutense de Madrid
Fecha de defensa: 25 mai 2022
- Aranzazu Sanchez Muñoz President
- Elisa Fernández Millán Secrétaire
- Carmen Gómez Guerrero Rapporteur
- Carmelo García Monzón Rapporteur
- Angela María Martínez Valverde Rapporteur
Type: Thèses
Résumé
Insulin resistance and altered glucose and lipid metabolism stand out among the main obesity-associated complications. This condition can lead to the development of comorbidities, such as non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes mellitus (DM2), which have common features. NAFLD is the most common liver pathology in Western countries, whose prevalence is continuously growing. This manifestation is mainly defined by the presence of steatosis in more than 5% of hepatocytes and its progression can cause non-alcoholic steatohepatitis (NASH). Although there are well-characterized factors involved in the progression of steatosis to NASH, such as lipotoxicity, oxidative stress and immune system activation, many others are still unknown. Due to the lack of treatment for this disease, it is necessary to deepen the knowledge of new mediators, including microRNAs (miRNAs), and therapeutic approaches, such as gene therapy, to prevent the development and progression of NAFLD...